WO2009150255A3 - Markers for predicting response and survival in anti-egfr treated patients - Google Patents

Markers for predicting response and survival in anti-egfr treated patients Download PDF

Info

Publication number
WO2009150255A3
WO2009150255A3 PCT/EP2009/057393 EP2009057393W WO2009150255A3 WO 2009150255 A3 WO2009150255 A3 WO 2009150255A3 EP 2009057393 W EP2009057393 W EP 2009057393W WO 2009150255 A3 WO2009150255 A3 WO 2009150255A3
Authority
WO
WIPO (PCT)
Prior art keywords
survival
markers
treated patients
predicting response
egfr
Prior art date
Application number
PCT/EP2009/057393
Other languages
French (fr)
Other versions
WO2009150255A2 (en
Inventor
Pierre Laurent-Puig
Steve Stone
Julia E. Reid
Original Assignee
Institut National De La Sante Et De La Recherche Medicale (Inserm)
Myriad Genetics Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National De La Sante Et De La Recherche Medicale (Inserm), Myriad Genetics Inc. filed Critical Institut National De La Sante Et De La Recherche Medicale (Inserm)
Publication of WO2009150255A2 publication Critical patent/WO2009150255A2/en
Publication of WO2009150255A3 publication Critical patent/WO2009150255A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Abstract

The invention generally relates to molecular diagnostics, and particularly to molecular markers for response and survival in patients treated with anti- EGFR therapeutics, as well as methods of use thereof.
PCT/EP2009/057393 2008-06-13 2009-06-15 Markers for predicting response and survival in anti-egfr treated patients WO2009150255A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US6152908P 2008-06-13 2008-06-13
US61/061,529 2008-06-13
US7778908P 2008-07-02 2008-07-02
US61/077,789 2008-07-02

Publications (2)

Publication Number Publication Date
WO2009150255A2 WO2009150255A2 (en) 2009-12-17
WO2009150255A3 true WO2009150255A3 (en) 2010-02-25

Family

ID=40904175

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/EP2009/057393 WO2009150255A2 (en) 2008-06-13 2009-06-15 Markers for predicting response and survival in anti-egfr treated patients
PCT/EP2009/057394 WO2009150256A1 (en) 2008-06-13 2009-06-15 Markers for predicting response and survival in anti-egfr treated patients

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/057394 WO2009150256A1 (en) 2008-06-13 2009-06-15 Markers for predicting response and survival in anti-egfr treated patients

Country Status (1)

Country Link
WO (2) WO2009150255A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070053205A (en) 2004-09-17 2007-05-23 에자이 알앤드디 매니지먼트 가부시키가이샤 Medicinal composition
WO2011109625A1 (en) * 2010-03-03 2011-09-09 Targeted Molecular Diagnostics, Llc Methods for determining responsiveness to a drug based upon determination of ras mutation and/or ras amplification
EP2640860A4 (en) * 2010-11-19 2014-06-04 Univ California Compositions and methods for detection and treatment of b-raf inhibitor-resistant melanomas
JP5952810B2 (en) * 2011-05-17 2016-07-13 エーザイ・アール・アンド・ディー・マネジメント株式会社 Methods for predicting the effects of angiogenesis inhibitors
WO2012166899A2 (en) 2011-06-03 2012-12-06 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
BR112015009004A8 (en) 2012-12-21 2021-07-20 Eisai R&D Man Co Ltd amorphous form of quinoline derivative and method of production thereof
CA2912219C (en) 2013-05-14 2021-11-16 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
KR20230043234A (en) 2014-08-28 2023-03-30 에자이 알앤드디 매니지먼트 가부시키가이샤 High-purity quinoline derivative and method for manufacturing same
AU2016224583B2 (en) 2015-02-25 2021-06-03 Eisai R&D Management Co., Ltd. Method for suppressing bitterness of quinoline derivative
KR20170122809A (en) 2015-03-04 2017-11-06 머크 샤프 앤드 돔 코포레이션 A combination of a PD-1 antagonist and a VEGFR / FGFR / RET tyrosine kinase inhibitor to treat cancer
CA2988707C (en) 2015-06-16 2023-10-10 Eisai R&D Management Co., Ltd. Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer
AU2016333538B2 (en) * 2015-10-02 2022-03-31 Julius-Maximilians-Universität Würzburg GDF-15 as a diagnostic marker to predict the clinical outcome of a treatment with immune checkpoint blockers

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006107854A2 (en) * 2005-04-01 2006-10-12 Amgen Inc. Epidermal growth factor receptor gene copy number

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2506066A1 (en) * 2002-11-15 2004-06-03 Genomic Health, Inc. Gene expression profiling of egfr positive cancer
JP2009523709A (en) * 2005-12-16 2009-06-25 ジェネンテック・インコーポレーテッド Methods for diagnosis, prognosis prediction and treatment of glioma
US20100003247A1 (en) * 2006-10-27 2010-01-07 George Mason Intellectual Properties, Inc. Assay for metastatic colorectal cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006107854A2 (en) * 2005-04-01 2006-10-12 Amgen Inc. Epidermal growth factor receptor gene copy number

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
AMANN J ET AL: "Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD., US, vol. 65, no. 1, 1 January 2005 (2005-01-01), pages 226 - 235, XP002397276, ISSN: 0008-5472 *
CAPPUZZO F ET AL: "EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients.", ANNALS OF ONCOLOGY : OFFICIAL JOURNAL OF THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY / ESMO APR 2008, vol. 19, no. 4, April 2008 (2008-04-01), pages 717 - 723, XP002547805, ISSN: 1569-8041 *
CAPPUZZO F ET AL: "EPIDERMAL GROWTH FACTOR RECEPTOR GENE AND PROTEIN AND GEFITINIB SENSITIVITY IN NON-SMALL-CELL LUNG CANCER", JOURNAL OF THE NATIONAL CANCER INSTITUTE, OXFORD UNIVERSITY PRESS, GB, vol. 97, no. 7, 4 May 2005 (2005-05-04), pages 643 - 655, XP009068788, ISSN: 0027-8874 *
HIRSCH F R ET AL: "Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib.", ANNALS OF ONCOLOGY : OFFICIAL JOURNAL OF THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY / ESMO APR 2007, vol. 18, no. 4, April 2007 (2007-04-01), pages 752 - 760, XP002547806, ISSN: 0923-7534 *
HIRSCH F R ET AL: "Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis", JOURNAL OF CLINICAL ONCOLOGY, AMERICAN SOCIETY OF CLINICAL ONCOLOGY, US, vol. 21, no. 20, 15 October 2003 (2003-10-15), pages 3798 - 3807, XP002397277, ISSN: 0732-183X *
HIRSCH F R ET AL: "INCREASED EPIDERMAL GROWTH FACTOR RECEPTOR GENE COPY NUMBER DETECTED BY FLUORESCENCE IN SITU HYBRIDIZATION ASSOCIATES WITH INCREASED SENSITIVITY TO GEFITINIB IN PATIENTS WITH BRONCHIOLOALVEOLAR CARCINOMA SUBTYPES A SOUTHWEST ONCOLOGY GROUP STUDY", JOURNAL OF CLINICAL ONCOLOGY, AMERICAN SOCIETY OF CLINICAL ONCOLOGY, US, vol. 23, no. 28, 1 October 2005 (2005-10-01), pages 6838 - 6845, XP009068790, ISSN: 0732-183X *
MORONI M ET AL: "Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study", LANCET ONCOLOGY, LANCET PUBLISHING GROUP, LONDON, GB, vol. 6, no. 5, 1 May 2005 (2005-05-01), pages 279 - 286, XP004870903, ISSN: 1470-2045 *
PAEZ J G ET AL: "EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, US, WASHINGTON, DC, vol. 304, no. 5676, 4 June 2004 (2004-06-04), pages 1497 - 1500, XP002359959, ISSN: 0036-8075 *
PERSONENI NICOLA ET AL: "Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH 15 SEP 2008, vol. 14, no. 18, 15 September 2008 (2008-09-15), pages 5869 - 5876, XP002547807, ISSN: 1078-0432 *
TAKANO T ET AL: "EPIDERMAL GROWTH FACTOR RECEPTOR GENE MUTATIONS AND INCREASED COPY NUMBERS PREDICT GETFITINIB SENSITIVITY IN PATIENTS WITH RECURRENT NON-SMALL-CELL LUNG CANCER", JOURNAL OF CLINICAL ONCOLOGY, AMERICAN SOCIETY OF CLINICAL ONCOLOGY, US, vol. 23, no. 28, 1 October 2005 (2005-10-01), pages 6829 - 6837, XP009068789, ISSN: 0732-183X *
VOGEL C L ET AL: "EFFICACY AND SAFETY OF TRASTUZUMAB AS A SINGLE AGENT IN FIRST-LINE TREATMENT OF HER2-OVEREXPRESSING METASTATIC BREAST CANCER", JOURNAL OF CLINICAL ONCOLOGY, AMERICAN SOCIETY OF CLINICAL ONCOLOGY, US, vol. 20, no. 3, 1 February 2002 (2002-02-01), pages 719 - 726, XP009069447, ISSN: 0732-183X *

Also Published As

Publication number Publication date
WO2009150255A2 (en) 2009-12-17
WO2009150256A1 (en) 2009-12-17

Similar Documents

Publication Publication Date Title
WO2009150255A3 (en) Markers for predicting response and survival in anti-egfr treated patients
WO2012088290A3 (en) Tri-variable domain binding proteins and uses thereof
WO2009129246A3 (en) Compositions and methods for preparing and using same
WO2008053444A3 (en) Treating a respiratory condition with bifidobacterium
WO2009108730A3 (en) Forms of rifaximin and uses thereof
WO2009108860A8 (en) Microrna-based methods and compositions for the diagnosis, pronosis and treatment of prostate related disorders
WO2009108856A3 (en) Microrna signatures associated with human chronic lymphocytic leukemia (ccl) and uses thereof
MY158992A (en) Forms of rifaximin and uses thereof
WO2008100805A3 (en) Anti-robo4 antibodies and uses therefor
EP2251081A4 (en) Catalyst, method for producing the same, and use of the same
WO2009158033A3 (en) Antagonists of activin-actriia and uses for increasing red blood cell levels
EP2308932A4 (en) Method for producing dye polymer, dye polymer and use of the same
MX2011009539A (en) Substituted 2-acetamido-5-aryl-1,2,4-triazolones and use thereof.
WO2008121616A3 (en) Antibodies with decreased deamidation profiles
IL209365A0 (en) Rocks and aggregate, and methods of making and using the same
IL214183A (en) Pharma-informatics system and method, composition for use therewith and method of preparing the composition
ZA201103584B (en) Whey protein compositions,methods and uses
WO2008089397A3 (en) Adrb2 cancer markers
WO2010062863A3 (en) Compositions containing satiogens and methods of use
WO2010077740A3 (en) Novel antiviral compounds, compositions, and methods of use
PL396375A1 (en) Compositions comprising arylpyrazole and / or formamidine, methods and uses thereof
EP2198962A4 (en) Catalyst, method for producing the same, and use of the same
IL200660A (en) Methods for production of 1,2-propanediol and modified e. coli for use in these methods
IL202674A0 (en) Genetic variants on chr 15q24 as markers for use in diagnosis, prognosis and treatment of exfoliation syndrome and glaucoma
EP2340297A4 (en) Composition, method of making the same, and use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09761816

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09761816

Country of ref document: EP

Kind code of ref document: A2